The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DMAA | N/A | N/A | N/A | +5% |
| S&P | +14.43% | +77.25% | +12.13% | +17% |
Drugs Made In America Acquisition Corp. is a blank check company. It is an exempt company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company was founded on May 23, 2024 and is headquartered in Fort Lauderdale, FL.
No news articles found for Drugs Made In America Acquisition Corp..
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $344.22M | 0.0% |
| Market Cap / Employee | $172.11M | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | $2.18M | 1607.3% |
| EBITDA | -$263.70K | -81.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.72K | -65.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.73% | 0.0% |
| Return On Invested Capital | 114.29% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$56.11K | 2.0% |
| Operating Free Cash Flow | -$56.11K | 2.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 355.32 | 103.76 | 60.95 | - | |
| Price to Book | -1370.72 | 1.51 | 1.51 | - | |
| Price to Tangible Book Value | -1371.65 | 1.51 | 1.51 | - | |
| Enterprise Value to EBITDA | -1015.05 | -2591.53 | -1305.35 | - | |
| Return on Equity | 2.9% | 4.9% | - | ||
| Total Debt | $662.32K | $60.90K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
